Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Abstract

Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).

Keywords

Affiliated Institutions

• Brigham and Women's Hospital US
• Fudan University CN
• Harvard University US
• Harefield Hospital GB
• Mayo Clinic US
• Ospedale Papa Giovanni XXIII IT
• Montreal Heart Institute CA
• National Medical Research Center of Cardiology RU
• University of Groningen NL
• Charité - Universitätsmedizin Berlin DE
• Sun Yat-sen University CN
• University Medical Center Groningen NL
• National Institute of Cardiovascular Diseases SK
• Medical University of Lodz PL
• Pontifícia Universidade Católica de Campinas BR
• Universidad Nacional de Córdoba AR
• National Heart Hospital BG
• University of Glasgow GB
• The First Affiliated Hospital, Sun Yat-sen University CN
• British Heart Foundation GB
• Baylor University Medical Center US
• Université de Lorraine FR
• Inserm FR
• Lung Institute US
• Centre Hospitalier Régional et Universitaire de Nancy FR
• Imperial College London GB
• Université de Montréal CA
• Zhongshan Hospital CN
• Bellvitge University Hospital ES
• Semmelweis University HU
• Universitat de Barcelona ES
• Medical University of South Carolina US
• Ralph H. Johnson VA Medical Center US
• German Centre for Cardiovascular Research DE

Related Publications